The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

PAOD1  -  Peripheral arterial occlusive disease 1

Homo sapiens

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PAOD1


Psychiatry related information on PAOD1


High impact information on PAOD1

  • We designate this locus as "PAOD1." Subtracting 35 patients with a history of stroke increased the LOD score to 4.93 [1].
  • PAOD often coexists with coronary artery disease and cerebrovascular disease [1].
  • Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31 [1].
  • CONCLUSIONS: In PAOD patients, there is a progressive reduction in urinary nitrate and cGMP excretion rates, which may be caused in part by accumulation of ADMA, an endogenous inhibitor of NO synthase [10].
  • Plasma L-arginine concentrations were not significantly different between the groups, but ADMA concentrations were elevated in PAOD patients (young control subjects, 1.25+/-0.11; elderly control subjects, 1.01+/-0.05 micromol/L; IIb, 2.62+/-0.24; III, 3.06+/-0.48; and IV, 3.49+/-0.26 micromol/L; P<.05 for PAOD versus control subjects) [10].

Chemical compound and disease context of PAOD1


Biological context of PAOD1


Anatomical context of PAOD1


Associations of PAOD1 with chemical compounds


Other interactions of PAOD1


Analytical, diagnostic and therapeutic context of PAOD1


  1. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Gudmundsson, G., Matthiasson, S.E., Arason, H., Johannsson, H., Runarsson, F., Bjarnason, H., Helgadottir, K., Thorisdottir, S., Ingadottir, G., Lindpaintner, K., Sainz, J., Gudnason, V., Frigge, M.L., Kong, A., Gulcher, J.R., Stefansson, K. Am. J. Hum. Genet. (2002) [Pubmed]
  2. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ernst, E., Resch, K.L. Ann. Intern. Med. (1993) [Pubmed]
  3. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Belch, J.J., Bell, P.R., Creissen, D., Dormandy, J.A., Kester, R.C., McCollum, R.D., Mizushima, Y., Ruckley, C.V., Scurr, J.H., Wolfe, J.H. Circulation (1997) [Pubmed]
  4. Predictors of the presence and extent of peripheral arterial occlusive disease. Drexel, H., Steurer, J., Muntwyler, J., Meienberg, S., Schmid, H.R., Schneider, E., Gröchenig, E., Amann, F.W. Circulation (1996) [Pubmed]
  5. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. O'Hare, A., Johansen, K. J. Am. Soc. Nephrol. (2001) [Pubmed]
  6. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. Kario, K., Matsuo, T., Hoshide, S., Umeda, Y., Shimada, K. Stroke (1999) [Pubmed]
  7. Dietary folate and vitamin B6 are independent predictors of peripheral arterial occlusive disease. Wilmink, A.B., Welch, A.A., Quick, C.R., Burns, P.J., Hubbard, C.S., Bradbury, A.W., Day, N.E. J. Vasc. Surg. (2004) [Pubmed]
  8. Smoking history is related to free-living daily physical activity in claudicants. Gardner, A.W., Montgomery, P.S., Womack, C.J., Killewich, L.A. Medicine and science in sports and exercise. (1999) [Pubmed]
  9. Peripheral arterial occlusive disease: clinical data for decision making. Introduction. Dormandy, J., Heeck, L., Vig, S. Seminars in vascular surgery. (1999) [Pubmed]
  10. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Böger, R.H., Bode-Böger, S.M., Thiele, W., Junker, W., Alexander, K., Frölich, J.C. Circulation (1997) [Pubmed]
  11. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. Böger, R.H., Bode-Böger, S.M., Thiele, W., Creutzig, A., Alexander, K., Frölich, J.C. J. Am. Coll. Cardiol. (1998) [Pubmed]
  12. Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Gorter, J.W., Oostenbrink, J.B., Tangelder, M.J. Thromb. Haemost. (2001) [Pubmed]
  13. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Money, S.R., Herd, J.A., Isaacsohn, J.L., Davidson, M., Cutler, B., Heckman, J., Forbes, W.P. J. Vasc. Surg. (1998) [Pubmed]
  14. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Dünser, M.W., Mayr, A.J., Tür, A., Pajk, W., Barbara, F., Knotzer, H., Ulmer, H., Hasibeder, W.R. Crit. Care Med. (2003) [Pubmed]
  15. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study. Ueki, Y., Matsumoto, K., Kizaki, Y., Yoshida, K., Matsunaga, Y., Yano, M., Miyake, S., Tominaga, Y., Eguchi, K. J. Thromb. Thrombolysis (1999) [Pubmed]
  16. Effects of oxygen inhalation on skin microcirculation in patients with peripheral arterial occlusive disease. Bongard, O., Bounameaux, H., Fagrell, B. Circulation (1992) [Pubmed]
  17. Management of peripheral vascular disease. Baumgartner, I., Schainfeld, R., Graziani, L. Annu. Rev. Med. (2005) [Pubmed]
  18. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Williams, D.T., Harding, K.G., Price, P. Diabetes Care (2005) [Pubmed]
  19. Indium-111-labeled platelet scintigraphy in carotid atherosclerosis. Minar, E., Ehringer, H., Dudczak, R., Schöfl, R., Jung, M., Koppensteiner, R., Ahmadi, R., Kretschmer, G. Stroke (1989) [Pubmed]
  20. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Lenk, K., Adams, V., Lurz, P., Erbs, S., Linke, A., Gielen, S., Schmidt, A., Scheinert, D., Biamino, G., Emmrich, F., Schuler, G., Hambrecht, R. Eur. Heart J. (2005) [Pubmed]
  21. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Joukhadar, C., Klein, N., Frossard, M., Minar, E., Stass, H., Lackner, E., Herrmann, M., Riedmüller, E., Müller, M. Clin. Pharmacol. Ther. (2001) [Pubmed]
  22. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. Yoshitomi, Y., Kojima, S., Umemoto, T., Kubo, K., Matsumoto, Y., Yano, M., Sugi, T., Kuramochi, M. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  23. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Scheffler, P., de la Hamette, D., Gross, J., Mueller, H., Schieffer, H. Circulation (1994) [Pubmed]
  24. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. Ghilardi, G., Biondi, M.L., Battaglioli, L., Zambon, A., Guagnellini, E., Scorza, R. J. Vasc. Surg. (2004) [Pubmed]
  25. Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Suzuki, Y., Horio, T., Hayashi, T., Nonogi, H., Kitamura, K., Eto, T., Kangawa, K., Kawano, Y. Regul. Pept. (2004) [Pubmed]
  26. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Decrinis, M., Pilger, E., Stark, G., Lafer, M., Obernosterer, A., Lammer, J. Eur. Heart J. (1993) [Pubmed]
  27. C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Renner, W., Schallmoser, K., Gallippi, P., Krauss, C., Toplak, H., Wascher, T.C., Pilger, E. Atherosclerosis (2000) [Pubmed]
  28. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. Semba, C.P., Murphy, T.P., Bakal, C.W., Calis, K.A., Matalon, T.A. Journal of vascular and interventional radiology : JVIR. (2000) [Pubmed]
  29. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. Owen, R.S., Carpenter, J.P., Baum, R.A., Perloff, L.J., Cope, C. N. Engl. J. Med. (1992) [Pubmed]
  30. Vascular training with drug therapy in peripheral arterial occlusive disease. Labs, K.H., Pischel, T. Circulation (1995) [Pubmed]
  31. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Ernst, E. Circulation (1997) [Pubmed]
  32. Quantitative ultrasonographic studies of lower extremity flow velocities in health and disease. Fronek, A., Coel, M., Berstein, E.F. Circulation (1976) [Pubmed]
WikiGenes - Universities